Erythropoietin Drugs Market Size, Share, Growth, Trends, and Global Industry Analysis: Size, Share, Growth, Trends, and Global Industry Analysis By Type (Biologics and Biosimilars), By Products (Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa, and Others), By Indication (Hematology, Kidney Disorder, Cancer, and Others), and Region Forecast 2019 - 2030

Erythropoietin Drugs Market size was valued at US$ 7,594.7 million and is poised to grow at a CAGR OF x% from 2024 - 2030. The market pertains to pharmaceuticals containing erythropoietin or its analogues, used primarily to treat anaemia associated with chronic kidney disease and cancer. The erythropoietin drugs alleviate the symptoms of anaemia, improve patients' comfort, and reduce the need for blood transfusions. An increase in the prevalence of chronic kidney diseases, cancer-related anaemia, HIV, and neurological diseases stipulates the growth of the erythropoietin drugs market.

According to WHO, it is estimated that 40% of all children aged 6-59 months, 37% of pregnant women and 30% of women 15–49 years of age are affected by anaemia. Anaemia caused 50 million years of healthy life lost due to disability in 2019, globally.

According to the CDC, more than 37 million people in the U.S. suffered from chronic kidney disease (CKD) in 2021. In CKD, the RBC production decreases significantly, resulting in anaemia. The rising number of CKD cases is thus expected to boost demand for erythropoietin drugs over the forecast period.

Furthermore, the erythropoietin drugs market is experiencing growth due to the increasing commercialization of erythropoietin biosimilars, accessible reimbursement options, supportive government regulations, and heightened awareness regarding the advantages of erythropoietin drug therapies. Side effects associated with erythropoietin drugs including arterial hypertension, iron deficiency, and influenza-like syndrome and longer duration of EPO treatment (4-6 weeks) restrain growth of the erythropoietin drugs market. Intense competition from the introduction of alternative medications is anticipated to decelerate market expansion in Japan. 

Erythropoietin Drugs Market Key Developments:

• In October 2023, Genexine, a prominent South Korean biopharmaceutical company, and KGbio, a clinical-stage biotechnology company, announced that they had received the first market approval for novel long-acting Erythropoietin, Efepoetin alfa, from The Indonesian Food and Drug Authority (BPOM).
• In November 2022, Dong-A ST and Polifarma inked a strategic agreement for the DA-3880 NESP biosimilar. Polifarma gained commercialization and development rights for DA-3880 in Brazil, Mexico, and Turkey.